ASCO: Gilead and Arcus’s Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates

June 3, 2023 |

1 min read

Editor’s note (June 5): This story has been removed from the BioSpace website because it was errantly posted without editorial review.

Gilead Sciences, Inc. Arcus Biosciences, Inc. Roche